Drugs / LCAR-F33S
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07100067 | Sep 2025 → Feb 2028 expected | plasma cell myeloma | Nanjing Legend Biotech Co. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LCAR-F33S | “A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of...” NCT07100067 ↗ |
| Modality | Cell therapy | “LCAR- F33S Cell Therapy” NCT07100067 ↗ |
| Route | Intravenous | “receive intravenous injection of LCAR-F33S cell injection” NCT07100067 ↗ |